J&J, GSK meds join Sovaldi, Tecfidera in blockbuster-to-be crowd

Gilead's Sovaldi--Courtesy of Gilead

New drug approvals may have dropped from 2012's high of 43 to 35 last year. But that doesn't mean 2013's crop lacks superstars. On the contrary, 9 newcomers--led by Gilead's ($GILD) hep C wonder Sovaldi--should crack the blockbuster barrier by 2018, according to a new report. And that includes drugs from Johnson & Johson ($JNJ), GlaxoSmithKline ($GSK) and Biogen Idec ($BIIB). Report